Latest YM BioSciences Inc. Stories

MISSISSAUGA, ON, Nov. 11, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer-related products, today reported operational and financial results for its first quarter of fiscal 2012, ended September 30, 2011. "During the quarter, we completed enrollment for the 166 patient Phase I/II trial of our JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. We look forward to presenting updated data...

MISSISSAUGA, ON, Nov. 7, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would report updated results from its Phase I/II myelofibrosis study of CYT387, a JAK1/JAK2 inhibitor, in a poster session to be held from 6:00pm - 8:00pm on Monday, December 12th at the 53rd Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, California. The Company also reported updated results today from the study that were included in an...

- Phase II Study of Nimotuzumab in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma (DIPG) MISSISAUGA, ON, Oct. 31, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP)...

- Company announces Annual and Special Meeting of Shareholders and appoints new head of Strategic Alliances - MISSISAUGA, ON, Oct. 19, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM) today announced that Catherine Mackey, Ph. D., former Senior Vice President of Worldwide Research and Development for Pfizer Inc., and Nicole Onetto, M.D., Deputy Director of the Ontario Institute for Cancer Research (OICR), have been proposed for nomination to the Company's Board...

- Six leading academic centers in the U.S. and Canada to recruit 60 patients into JAK1/JAK2 inhibitor twice-daily study - MISSISSAUGA, ON, Sept. 28, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM) today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis. The trial will further evaluate the safety and tolerability of YM's JAK1/JAK2 inhibitor, as well as...

MISSISSAUGA, ON, Sept. 26, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden. A poster presentation entitled "Phase 2 study of nimotuzumab in combination with...

TORONTO, Sept. 23, 2011 /PRNewswire/ - In a release issued today, September 23, 2011, at 07:00 ET entitled "YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results", an error occurred in the fifteenth paragraph. The Company reported the net loss for the fourth quarter of fiscal 2011 was $8.0 million ($0.08 per share). The net loss per share should be "($0.07 per share)" not "($0.08 per share)". SOURCE YM BioSciences Inc.

- Enrollment of Phase I/II trial for CYT387 complete - MISSISSAUGA, ON, Sept. 23, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE: YMI), (TSX: YM), a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011. "During fiscal 2011, we refocused YM's efforts primarily onto the advancement of our JAK1/JAK2 inhibitor, CYT387. This strategy...

- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011. The results demonstrate that CYT387 can inhibit MM...

MISSISSAUGA, ON, July 7, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM) (the "Company"), today announced it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada and a registration statement on Form F-10 with the United States Securities and Exchange Commission. Once the shelf prospectus is cleared and the registration statement becomes effective, these filings will, subject to applicable securities regulatory...